Lonza Group stock holds near mid-range as investors digest 2024 earnings reset

Lonza Group (ISIN CH0013841017) stock is trading around CHF 450 per share on SIX Swiss Exchange as of August 12, 2026, leaving the company’s market capitalization near CHF 38 billion while investors continue to digest the earnings reset that followed its 2024 results.

Valuation anchored by recent price and range

According to recent coverage of Lonza Group, shares are changing hands at roughly CHF 450 as of August 12, 2026, compared with a 52 week high of about CHF 520 and a low near CHF 420, placing the current price close to the middle of that trading range.

At the CHF 450 level, the same overview indicates Lonza’s market capitalization is around CHF 38 billion as of August 12, 2026, versus approximately CHF 44 billion when the stock traded near its CHF 520 peak, implying a decline of roughly CHF 6 billion in equity value that tracks the reduced earnings power signaled in earlier guidance.

Earnings reset reflected in 2024 fundamentals

Per Lonza Group’s published full year 2024 figures summarized in the same investor-focused report, the company generated around CHF 6.0 billion in group sales in 2024, down from roughly CHF 6.7 billion in 2023 as contract manufacturing volumes normalized after the pandemic period and the company exited its drug product manufacturing operations.

The 2024 release also shows that core EBITDA declined to approximately CHF 1.6 billion in 2024 from about CHF 1.9 billion in 2023, highlighting how lower capacity utilization and ongoing investments in new biologics plants compressed profitability and reduced margins versus the prior year.

In net profit terms, the 2024 numbers indicate Lonza delivered roughly CHF 0.9 billion in profit from continuing operations, compared with around CHF 1.1 billion in 2023, underscoring that 2024 was a transition year with a meaningful earnings step-down of about CHF 0.2 billion that investors have been incorporating into valuation multiples.

Biologics manufacturing as a core business

Lonza Group’s business is anchored in contract development and manufacturing services for the pharmaceutical and biotechnology industry, with biologics manufacturing representing one of its largest and strategically important segments.

Within this segment, Lonza typically supports customers by developing and scaling up processes for monoclonal antibodies and other complex biologic therapies, providing both clinical and commercial-scale production capacity that is crucial for global drug launches.

Stock level and investor takeaway

As of August 12, 2026, Lonza Group stock at around CHF 450 on SIX Swiss Exchange trades near the midpoint of its indicated 52 week range between roughly CHF 420 and CHF 520, a level that reflects the earnings reset visible in the 2024 results but still assigns a substantial valuation of about CHF 38 billion to the company.